Saturday, May 18, 2024
5/18/2024
SUMMARY/ABSTRACT There are currently more than 280 genes in which defects are known to cause retinal degeneration. Thus, there is a critical need to develop broad spectrum approaches to treating these diseases. The hypothesis of this proposal is that if we can selectively increase glycolysis in rod and cone photoreceptors, then this increase in metabolic potential should slow retinal degeneration across a broad spectrum of etiologies. Our findings strongly support the idea that we can specifically modify arrestin1 such that the catalytic rate of enolase1 in glycolysis is selectively increased in rods and cones. Significantly, this increase in glycolysis slows the loss of photoreceptors and improves photoreceptor function in at least one animal model of retinal degeneration. Accordingly, the specific aims of this proposal are to determine the mechanistic properties of ArrGG’s effect, examining metabolites and gene expression profiles of treated animals (Aim1). We will then establish ArrGG as a gene-agnostic approach to slowing retinal degeneration, testing the therapeutic benefit of ArrGG in diverse models of inherited retinal degeneration (Aim 2).
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
